Cipla (CIPLA) Share Price & Analysis
Cipla (CIPLA) — Drug Manufacturers - Specialty & Generic
Cipla Key Fundamental Metrics
Executive Investment Overview & Business Profile
Cipla commands a premium valuation with a P/E of 35.3942, supported by high market dominance and profitability expectations.
Cipla is one of the premier companies in India's Healthcare sector. Currently trading at ₹1,477 with a market capitalization of ₹1.19 Lakh Cr, the company occupies a key position in the Indian equity market.
Investors evaluating Cipla focus closely on its capital return metrics: Return on Equity (ROE) stands at N/A alongside operating margins of 12.55%. The company's earnings multiple of 35.3942 P/E provides a clear signal of market expectation relative to sector peers.
Company Profile & Information
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.